Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2024, reporting record net sales and significant progress across its product categories and key future growth drivers.

• Record net sales: Achieved 3.259 billion USD in net sales during the first nine months of 2024, up +9.2% year-on-year in constant currency1, predominantly driven by volume growth, complemented by favorable mix. Galderma also achieved the highest third quarter net sales in its history
• Broad-based growth: Continued performance across all product categories with sustained double-digit growth in Injectable Aesthetics and Dermatological Skincare, with constant currency year on-year growth of 10.6% for Injectable Aesthetics, 10.6% for Dermatological Skincare, and 2.9% for Therapeutic Dermatology for the first nine months of 2024
• Focused strategic execution: Continued progress against the company’s growth-focused Integrated Dermatology Strategy, advancing all its product categories and future growth drivers through key approvals and bringing to market new products, including Nemluvio® (nemolizumab) for adult patients with prurigo nodularis in the U.S.
• New promising clinical data: Reaffirmed commitment to leading in dermatology with the release of new data, including nemolizumab late-breaking results from ARCADIA and OLYMPIA clinical trial programs in atopic dermatitis and prurigo nodularis
• 2024 full year guidance confirmed and narrowed on net sales: Full year net sales growth expected to be in the range of 8.8-9.5% year-on-year at constant currency (previously expected towards the upper end of the 7-10% growth range at constant currency), and for Core EBITDA margin expected to be in line with 2023 at constant currency